利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.015 秒)

    CRF receptor antagonists and methods relating thereto
    2.
    发明授权
    CRF receptor antagonists and methods relating thereto 失效
    CRF受体拮抗剂及其相关方法

    公开(公告)号：US06541469B2

    公开(公告)日：2003-04-01

    申请号：US09861472

    申请日：2001-05-18

    申请人： Mustapha Haddach

    发明人： Mustapha Haddach

    IPC分类号： A61K31542

    CPC分类号： C07D487/16 ,  C07D498/16

    摘要： CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein X is nitrogen or CR3; A is O, S, or NR4, and R, R1, R2are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

    摘要翻译： 公开了CRF受体拮抗剂，其可用于治疗各种疾病，包括治疗在温血动物（例如中风）中表现出CRF过度分泌的病症。 本发明的CRF受体拮抗剂具有以下结构：包括立体异构体及其药学上可接受的盐，其中X为氮或CR 3; A是O，S或NR4，R，R1，R2如本文所定义。 还公开了含有CRF受体拮抗剂与药学上可接受的载体的组合物，以及其用途的方法。

    Positive allosteric AMPA receptor modulators
    3.
    发明授权
    Positive allosteric AMPA receptor modulators 有权
    正变构AMPA受体调节剂

    公开(公告)号：US06525045B2

    公开(公告)日：2003-02-25

    申请号：US09774864

    申请日：2001-01-31

    申请人： Karin Winter ,  Thomas Weiser ,  Stefan M. Blech ,  Angelo Ceci

    发明人： Karin Winter ,  Thomas Weiser ,  Stefan M. Blech ,  Angelo Ceci

    IPC分类号： A61K31542

    CPC分类号： C07D513/06

    摘要： The present invention relates to new positive allosteric AMPA receptor modulators of general formula (I) wherein R1, R2 R3, R4, R5 and R6 may have the meanings indicated in the specification and claims, processes for preparing them and their use as pharmaceutical compositions.

    摘要翻译： 本发明涉及通式（I）的新的正变构AMPA受体调节剂，其中R 1，R 2，R 3，R 4，R 5和R 6可以具有说明书和权利要求书中指出的含义，其制备方法及其作为药物组合物的用途。

    Dipeptide derivatives
    4.
    发明授权
    Dipeptide derivatives 失效
    二肽衍生物

    公开(公告)号：US06432945B1

    公开(公告)日：2002-08-13

    申请号：US09822095

    申请日：2001-03-30

    申请人： Philip Albert Carpino ,  David Andrew Griffith ,  Bruce Allen Lefker

    发明人： Philip Albert Carpino ,  David Andrew Griffith ,  Bruce Allen Lefker

    IPC分类号： A61K31542

    CPC分类号： C07D487/04 ,  A61K38/00 ,  C07D471/04 ,  C07D491/04 ,  C07D513/04 ,  C07K5/0202 ,  C07K5/0205 ,  C07K5/0207 ,  C07K5/021 ,  C07K5/06026

    摘要： This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which increase the level of endogenous growth hormone. The compounds of this invention are useful for the treatment and prevention of osteoporosis and/or frailty, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair, attenuating protein catabolic response after a major operation, reducing cachexia and protein loss due to chronic illness, accelerating wound healing, or accelerating the recovery of burn patients or patients having undergone major surgery; improving muscle strength, mobility, maintenance of skin thickness, metabolic homeostasis or renal homeostasis. The compounds of the present invention are also useful in treating osteoporosis and/or frailty when used in combination with: a bisphosphonate compound such as alendronate; estrogen, premarin, and optionally progesterone; an estrogen agonist or antagonist; or calcitonin, and pharmaceutical compositions useful therefor. Further, the present invention is directed to pharmaceutical compositions useful for increasing the endogenous production or release of growth hormone in a human or other animal which comprises an effective amount of a compound of the present invention and a growth hormone secretagogue selected from GHRP-6, Hexarelin, GHRP-1, growth hormone releasing factor (GRF), IGF-1, IGF-2 or B-HT920. The invention is also directed to intermediates useful in the preparation of compounds of Formula I.

    摘要翻译： 本发明涉及式的化合物及其药学上可接受的盐，其中取代基如本说明书中所定义，其是生长激素分泌元素，并且其增加内源性生长激素的水平。 本发明的化合物可用于治疗和预防骨质疏松症和/或虚弱，充血性心力衰竭，与衰老相关的脆弱性，肥胖症; 加速骨折修复，减轻主要手术后的蛋白质分解代谢反应，减少慢性疾病引起的恶病质和蛋白质损失，加速伤口愈合，或加速烧伤患者或经历大手术的患者的恢复; 改善肌肉力量，移动性，维持皮肤厚度，代谢体内平衡或肾脏体内平衡。 当与以下物质组合使用时，本发明的化合物还可用于治疗骨质疏松症和/或虚弱：双膦酸盐化合物如阿仑膦酸盐; 雌激素，雌激素和可选的孕酮; 雌激素激动剂或拮抗剂; 或降钙素，以及对此有用的药物组合物。 此外，本发明涉及可用于增加人或其他动物中生长激素的内源性产生或释放的药物组合物，其包含有效量的本发明化合物和选自GHRP-6的生长激素促分泌素， Hexarelin，GHRP-1，生长激素释放因子（GRF），IGF-1，IGF-2或B-HT920。 本发明还涉及可用于制备式I化合物的中间体。